This weekend, we are attending #AANAM to share research findings from our neuroscience portfolio and pipeline with sleep, epilepsy and movement disorder experts. Read about our data and visit our Sleep Medical Affairs booth (#1632) onsite to learn more: bit.ly/4cJgCFM

This #JazzScienceWeek , hear from Mat Davis, VP and Head of Data Science, as he defines how we are using quantitative methods to expand our R&D reach to help transform the lives of patients and their families.

We are on site with partners at #AACR2024 this week to share new data from our expanding pipeline and growing focus in targeted #oncology . Watch our #PioneeringPathways video to learn more: bit.ly/4cK4PqQ

We completed the submission of a Biologics License Application to the FDA for accelerated review for our bispecific antibody as a potential treatment for previously-treated, unresectable locally advanced, or metastatic HER2-positive biliary tract #cancer . bit.ly/4axVWP2

Idiopathic #hypersomnia (IH) is a multi-symptom sleep disorder that is often misunderstood and misdiagnosed as other conditions. This #SleepAwarenessMonth , watch our #PioneeringPathways video to learn how Jazz is pioneering innovative solutions in IH: bit.ly/3VohYPZ

During our R&D Day focused on HER2-targeted therapies, we shared data from our investigational HER2-targeted bispecific antibody in patients with metastatic breast cancer (mBC), and announced a new Phase 3 trial in #HER2 + #mBC following prior targeted therapy.

As part of our R&D Day today focused on HER2-targeted therapies, Santiago Escrivá-de-Romani, MD, discusses advancements in HER2+ research for metastatic breast cancer (mBC), a cancer type with significant unmet need. Learn about our expanding pipeline: bit.ly/48zl3Aw

As part of our R&D Day today focused on HER2-targeted therapies, Geoffrey Y. Ku, MD of Memorial Sloan Kettering Cancer Center discussed unmet needs in gastroesophageal adenocarcinoma cancer (GEA) and the potential of HER2-targeted therapies in GEA. Learn about our pipeline: bit.ly/48zl3Aw

Today during our R&D Day focused on HER2-targeted therapies, we’re sharing data from our pipeline of investigational medicines. Visit #PioneeringPathways to learn more about our bispecific antibody targeting multiple HER2-expressing tumors: bit.ly/3TNDcWO (U.S. only)

Tomorrow, we’re hosting an R&D Day focused on HER2-targeted therapies. Hear Stefan Faderl, MD, VP, Therapeutic Area Head, Oncology Clin. Dev, delve into the role of HER2 in cancer cells, and learn more about tomorrow’s event here: bit.ly/3IUVlLT

#Essentialtremor (ET) is the most common movement disorder worldwide, yet there are few approved medicines available to treat it. This ET Awareness Month, learn about the potential new treatment option we’re exploring to address this urgent need: bit.ly/4c5hCne

Jazz announces fourth quarter and full year 2023 financial results $JAZZ: bit.ly/42Y40Go

We’re pleased to welcome a new independent director, Patrick Kennedy, to the Jazz Board of Directors. Learn more: bit.ly/3wxxxdQ

Over 210,000 people globally are diagnosed with biliary tract cancer every year, often at an advanced stage. This #Cholangingiocarcinoma Awareness Month, Elaina Gartner, VP Medical, Late-Stage/Oncology Clin. Dev., delves into the role #HER2 plays in BTC. bit.ly/3uAgveF

We are pleased to announce the appointment of Phil Johnson as our new EVP & Chief Financial Officer. We look forward to the level of expertise that he will bring to this role, as we continue innovating to transform the lives of patients and their families. bit.ly/3T58RCa

Research has shown that sleep disorders may contribute to the development of cardiovascular risk factors and events. This #HeartMonth , learn more about the association between disrupted sleep and cardiovascular risk: bit.ly/497J027

Today we announced a definitive agreement under which Jazz will acquire Redx Pharma's KRAS inhibitor program. This transaction further expands our early-stage #oncology pipeline, and we are excited to explore novel treatment options for #cancer patients. bit.ly/3SPN2GU

#WorldCancerDay demonstrates the power of collaboration in the effort to reduce the impact of cancer and #CloseTheCareGap for the millions of people impacted worldwide. Learn more about our efforts to help raise the standards of cancer care (U.S. only): bit.ly/3OuKrPQ

We are committed to pursuing research approaches that address rare #epilepsy syndromes, including Dravet syndrome, Lennox-Gastaut syndrome (LGS) and tuberous sclerosis complex (TSC). Learn more about these syndromes and our commitment to advancing treatment options for patients.

Jazzicians and their families nationwide recognized #MLKDay this week by volunteering at local food banks, aiming to combat hunger in food insecure areas and make a positive impact on the lives of those in our community.